Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

• Status: Completed
• Trial end date: 2011-05-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fluticasone; Xhance

Criteria

Inclusion Criteria:

• Clinical diagnosis of asthma

• Reversibility FEV1 of twelve percent or greater and two hundred milliliters and greater approximately ten to forty minutes following two to four inhalations of albuterol

• FEV1 greater than or equal to fifty percent of predicted

• Currently using moderate to high dose inhaled corticosteroid therapy

Exclusion Criteria:

• History of life threatening asthma

• Respiratory infection or oral candidiasis

• Asthma exacerbation

• Uncontrolled disease or clinical abnormality

• Allergies

• Taking another investigational medication or prohibited medication